Topotecan, an active new antineoplastic agent: review and current status

Bibliography

• ECKARDT J, ECKHARDT G, VILLALONA-CALERO M, DRENGLER R, VON HOFF D: New anticancer agents in clinical development. Oncology (1995) 9:1191–1199.
   PubMedGoogle Scholar
• XIE Z-F, OOTSU K, AKIMOTO H: Convergent approach to water soluble camptothecin derivatives. Bioorg. Med. Chem. Leff. (1995) 5:2189–2194.
   Web of Science ®Google Scholar
• ARDIZZONI A: Camptothecin analogues in the treat-ment of non-small cell lung cancer. Lung Cancer (1995) 12 (Suppl. 1):S177–S185.
   Google Scholar
• KUHN J, BURRIS S, WALL J eta].: Pharmacokinetics of the topoisomerase I inhibitor, SK&F 104864. Proc. ASCO (1990) 9:269.
   Google Scholar
• UNDERBERG WJM, GOOSEN RMJ, SMITH BR, BEIJEN JH:
   Google Scholar
• •Equilibrium kinetics of the new experimental anti-tu-mour compound SK&F 104864-A in aqueous solution. Pharm. Biomed. Analysis (1990) 8:681-683. Topotecan kinetics in solution.
   Google Scholar
• HSIANG YH, LIU LF: Identification of mammalian DNA topoisomerase I as an intracellular target of the anti-cancer drug camptothecin. Cancer Res. (1988) 48:1722-1726. Mechanism of action of topoisomerase I inhibition.
   Google Scholar
• CREEMERS GJ, LUND B, VERWEIJ J: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev. (1994) 20:73–96.
   PubMed Web of Science ®Google Scholar
• SCHELLENS JMH, PRONK LC, VERWEIJ J: Emerging drug treatments for solid tumours. Drugs (1996) 51:45–72.
   PubMed Web of Science ®Google Scholar
• BEEN MD, BURGESS RR, CHAMPOUX JJ: Nucleotide se-quence preference at rat liver and wheat germ type I DNA topoisomerase breakage sites in duplex SV40 DNA. Nucleic Acids Res. (1984) 12:3097–4014.
   PubMed Web of Science ®Google Scholar
• BURRIS HA, III, HANAUSKE A-R, JOHNSON RK et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. (1992) 84:1816–1820.
   PubMed Web of Science ®Google Scholar
• JOHNSON RK, MCCABE FL, FAUCETTE LF et al: SK&F 104864, a water-soluble analog of camptothecin with broad-spectrum activity in preclinical tumour models. Proc. AACR (1989) 30:623.
   Google Scholar
• JOHNSON RK, MCCABE FL, GALLAGHER G et al: Compara-tive efficacy of topotecan, irinotecan, camptothecin and G-amino-camptothecin in preclinical tumour models. Proc. 7th NC-EORTC Symposium on New Drugs in Cancer Therapy. Amsterdam (1992):85.
   Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, MYERS L et al.: Evaluation of 9-dimethyl-aminomethy1-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol (1992) 31:229-239. Topotecan activity in human tumour models.
   Google Scholar
• FRIEDMAN HS, HOUGHTON PJ, SCHOLD SC et al: Activity of 9-dimethyl-aminomethy1-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. Cancer Chemother. Pharmacol (1994) 34:171–174.
   PubMed Web of Science ®Google Scholar
• PRATESI G, TORTORETO M, CORTI C et al: Successfullocal regional therapy with topotecan of intraperi-toneally growing human ovarian carcinoma xenografts. Br. J. Cancer (1995) 71:525–528.
   PubMed Web of Science ®Google Scholar
• CHOU TC, MOTZER RJ, TONG Y et al: Computerized quantitation of synergism and antagonism of taxol, topotecan and cisplatin against human teratocarci-noma cell growth: a rational approach to clinical pro-tocol design. J. Natl. Cancer Inst. (1994) 86:1517–1524.
   PubMed Web of Science ®Google Scholar
• TEICHER BA, HOLDEN SA, KHANDAKAR V et al: Additionof a topoisomerase I inhibitor to trimodality therapy cis -dia mmine dichloro-platinum(Il) /he at/r adi ation in a murine tumor. J. Cancer Res. Clin. Oncol. (1993) 119:645–651.
   PubMed Web of Science ®Google Scholar
• BERTRAND R, O'CONNER PM, KERRIGAN D et al: Sequen-tial administration of camp tothecin and etoposide cir-cumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer (1992) 28A:743–748.
   PubMed Web of Science ®Google Scholar
• KUHN J, IRVIN R, KANE B et al: Pharmacokinetics of topotecan following a 30 min infusion or 3 day continu-ous infusion. Pharmacotherapy (1992) 12:23E.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, LUND B, BEIJNEN J et aL: Phase! and pharma-cokinetic study of topotecan, a new topoisomerase I inhibitor. Ann. Oncol (1993) 4:673-678. Pharmacokinetics of topotecan daily x 5 schedule.
   Google Scholar
• DAVIES B, BEIJNEN J, VERWEIJ J: Pharmacokinetics of topotecan, a novel topoisomerase I inhibitor, in cancer patients. AAPS (1993) 10(10 Suppl.):S335.
   Google Scholar
• ROWINSKY EK: Topoisomerase I inhibition and phar-macokinetic profile of Hycamtiring. ESMO Satellite Sym-posium. Vienna (1996).
   Google Scholar
• VAN WARMERDAM LJC, TEN BOKKEL HUININK WW, RODENHUIS S et al.: Phase I clinical and pharmacoki- netic study of topotecan administered by a 24-hour continuous infusion. J. Clin. Oncol. (1995) 13:1768-1776. Pharmacokinetics and MTD of topotecan continuous intravenous infusion.
   Google Scholar
• BURRIS HA, III, AWADA A, KUHN JG et al.: Phase I andpharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion. Anti-Cancer Drugs (1994) 5:394–402.
   PubMed Web of Science ®Google Scholar
• HOCHSTER H, LIEBES L, SPEYER J et al: Phase I trial oflow-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J. Clin. Oncol (1994) 12:553–559.
   PubMed Web of Science ®Google Scholar
• WALL JG, BURRIS HA, III, VON HOFF DD et al.: A Phase Iclinical and pharmacokinetic study of the topoisom-erase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anti-Cancer Drugs (1992) 3:337–345.
   Google Scholar
• GROCHOW LB, ROWINSKY EK, JOHNSON R et al.: Phar-macokinetics and pharmacodynamics of topote can in patients with advanced cancer. Drug Metab. Disp. (1992) 20:706–713.
   PubMed Web of Science ®Google Scholar
• HASEGAWA K, NISHIMURA R, FUKUOKA M etal: Phase Iand pharmacologic evaluation of topotecan on a 30-minutes infusion. Proc. AACR (1993) 34:A2514.
   Google Scholar
• RECONDO G, ABBRUZZESE J, NEWMAN B et al.: Phase Itrial of topotecan administered by a 24-hr infusion. Proc. AACR (1991) 32:A1229.
   Google Scholar
• SCHELLENS JMH, CREEMERS GIBEIJNEN JH et al: Bioavailability and pharmacokinetics of oral topotecan, a new topoisomerase I inhibitor. Br. J. Cancer (1996) 73:1268-1271. Bioavailability of oral topotecan.
   Google Scholar
• KUHN J, RIZZO J, ECKARDT J et aL: Phase I bioavailabilitystudy of oral topotecan. Proc. ASCO (1995) 14:1538A.
   Google Scholar
• VAN WARMERDAM LJC, VERWEIJ J, SCHELLENS JHM eta].:Pharmacokinetics and pharmacodynamics of topote-can administered daily for 5 days every three weeks. Cancer Chemother. Pharmacol (1995) 35:237–245.
   Google Scholar
• HOCHSTER H, LIEBES A, JACQUOTTE Z et al.: Pharma-codynamics of 21 day topotecan infusion in a Phase II study of ovarian cancer: correlation with TPT admini-stration and haem toxicity. Proc. ASCO (1996) 15:1507A.
   Google Scholar
• O'REILLY S, ROWINSKY EK, SLICHENMYER W et al: Phaseland pharmacologic study of topotecan inpatients withimpaired renal function. J. Clin. Oncol. (1996) 14:3062-3073. Use of topotecan in patients with impaired renal function.
   Google Scholar
• Hycamtin prescribing information. December 1995.
   Google Scholar
• SLICHENMYER W, CHEN T, DONEHOWER R et al: Clinical pharmacology of topotecan in cancer patients with renal or hepatic dysfunction. Proc. ASCO (1994) 13:142. MTD of topotecan daily x 5 schedule in renal and hepatic impair-ment.
   Google Scholar
• O'REILLY S, ROWINSKY E, SLICHENMYER W et al: PhaseI and pharmacologic studies of topotecan in patients with impaired hepatic function. J. Natl. Cancer Inst. (1996) 88:817–824.
   PubMedGoogle Scholar
• ROWINSKY EK, GROCHOW LB, HENDRICKS CB et al.:
   Google Scholar
• ••Phase land pharmacologic study of topotecan: a noveltopoisomerase I inhibitor. J. Clin. Oncol (1992) 10:647-656. MTD of topotecan daily x 5 regimen.
   Google Scholar
• SALTZ L, SIROTT M, YOUNG C etal: Phase I clinical andpharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tu-mours, with attempt at dose intensification using re-combinant granulocyte colony-stimulating factor. J. Natl. Cancer Inst. (1993) 85:1499–1507.
   PubMed Web of Science ®Google Scholar
• ROWINSKY E, KAUFMAN S, BAKER S et al: Phase I,pharmacologic and pharmacodynamic study of the topoisomerase I inhibitor topotecan (TPT) in adults with refractory acute leukaemia. Ann. Oncol (1996) 7 (Suppl .):132.
   Google Scholar
• ROWINSKY E, SARTORIUS S, GROCHOW L et al.: Phase Iand pharmacologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): toxicologic differences between concur-rent and post-treatment G-CSF administration. Proc. ASCO (1992) 11:A284.
   Google Scholar
• ROWINSKYEK, GROCHOW LB, SARTORIUS SE eta].: Phase I and pharmacologic study of high doses of the topoi-somerase I inhibitor topotecan with granulocyte col-ony-stimulating factor in patients with solid tumors. J. Oncol. (1996) 14:1224–1235.
   Google Scholar
• TUBERGEN D, PRATT C, STEWART C et al: Phase I study of topotecan in children with refractory solid tumours: a Pediatric Oncology Group Study. Proc. ASCO (1994) 13:167.
   Google Scholar
• ABBRUZZESE JL, MADDEN T, SCHMIDT S, EATON G, RABER MN: Phase I trial of topotecan (IT) administered by 24-hour infusion without and with G-CSF. Proc. AACR (1993) 34:329.
   Google Scholar
• HAAS NB, LACRETA FP, WALCZAK J eta].: Phase l/phar-macokinetic study oftopotecan by 24-hour continuous infusion weekly. Cancer Res. (1994) 54:1220–1226.
   Google Scholar
• SABIERS J, BERGER N, BERGER S et al: Phase I trial of topotecan administered as a 72 hour infusion. Proc. AACR (1993) 34:426.
   Google Scholar
• PRATT C, STEWART C, SANTANA V et aL: Phase I study of topotecan for pediatric patients with malignant solid tumours. J. Clin. Oncol. (1994) 12:539–543.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, BERAN M, ELLIS A eta].: Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood (1993) 81:1146–1151.
   Google Scholar
• ROWINSKY EK ADJEI A, DONEHOWER RC eta].: Phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J. Clin. Oncol. (1994) 12:2193–2203.
   Google Scholar
• HOCHSTER H, LIEBES L, ZELENIUCH-JACQUOTTE A eta].: Progressive cleavable complex (CC) formation with 21 day topotecan infusion: a Phase I pharmacodynamic study. Proc. ASCO (1995) 14:1496.
   Google Scholar
• GERRITS CJH, BURRIS H, SCHELLENS JMH et al: 5 days of once daily oral topotecan, a Phase I and pharmacologic study in adults. Ann. Oncol (1996) 7\(Suppl. 5):5970. MTD of oral topotecan.
   Google Scholar
• BURRIS H, GERRITS CJH, SCHELLENS JMH et al: Oral topotecan for 10 days once daily and twice daily every 3 weeks: a Phase I and pharmacologic study in adults. Ann. Oncol (1996) 7 (Suppl. 5):6050.
   Google Scholar
• GERRITS CJ, ECKARDT JR, SCHELLENS JHM et al: Oral topotecan for 10 days bid every 3 weeks, results of a Phase I study in adults with solid tumours. Ann. Oncol. (1996) 7(Suppl.):132.
   Google Scholar
• CREEMERS GJ, GERRITS CJH, ECKARDT JR et al: Phase I and pharmacologic study of oral topotecan adminis-tered twice daily for 21-days to patents with solid tumours. J. Clin. Oncol (1996) 15:1087–1093.
   Web of Science ®Google Scholar
• PLAXE S, CHRISTEN R, OQUIGLEY J etal.: Phase I trial of ip. topotecan. Proc. ASCO (1993) 12:A360.
   Google Scholar
• LILENBAUM RC, MILNE AA, BATIST G: Phase I study of continuous iv. infusion topotecan (TT) in combination with cisplatin (C) in patients with advanced cancer (CALGB 9462). Ann. Oncol (1996) 7(Suppl.):471. Synergism of topotecan and cisplatin
   Google Scholar
• MILLER AA, HARGIS JB, LILENBAUM RC eta].: Phase I study of topotecan and cisplatin in patients with advanced solid tumours: a Cancer and Leukemia Group B study. J. Clin. Oncol. (1994) 12:2743–2750.
   Google Scholar
• MILLER AA, LILENBAUM RC, LYNCH TJ et al.: Treatment-related fatal sepsis from topotecan/cisplatin and topo-tecan/paclitaxel. j Clin. Oncol (1996) 14:1964–1969.
   PubMed Web of Science ®Google Scholar
• ROTHENBERG ML, BURRIS H, ECKARDT D eta].: Phase I/IIstudy of topotecan and cisplatin in patients with non-small cell lung cancer (NSCLC). Proc. ASCO (1993) 12:A423.
   Google Scholar
• ROWINSKY E, GROCHOW L, KAUFMANN S et al: Se-quence-dependent effects of topotecan (1) and cisplatin (C) in a Phase land pharmacokinetic (PK) study. Proc. ASCO (1994) 13:142.
   Google Scholar
• MURREN JR, FEDELE J, ANDERSON S eta].: Phase I trial ofcyclophosphamide (clx) and topotecan (tpt) in refrac-tory cancer. Proc. ASCO (1995) 14:1542.
   Google Scholar
• HERBEN VMM, TEN BOKKEL HUININK WW, RODENHUIS S eta].:Phase land pharmacoki net ic study of topote can in combination with oral etoposide. Ann. Oncol. (1996) 7(Suppl ) 472
   Google Scholar
• CRUMP M, LIPTON J, HEDLEY E, EISENHAUER E: A Phase I trial of topotecan and etoposide in adult acute myeloid leukaemia. Ann. Oncol (1996) 7 (Suppl.):473.
   Google Scholar
• CRUMP M, LIPTON J, HFDLEY D eta].: A Phase I trial of sequential topotecan and etoposide in adult acute myeloid leukaemia (AML). Proc. ASCO (1996) 15:1050A.
   Google Scholar
• LILENBAUM RC, ROSNER GL, RATAIN MJ et al.: Phase I study of taxol and topotecan in patients with advanced solid tumours (CALGB 9362). Proc. ASCO (1994) 13:319.
   Google Scholar
• LILENBAUM RC, RATAIN MJ, MILLER AA eta].: Phase I study of paclitaxel and topotecan in patients with advanced tumours: a Cancer and Leukemia Group B study./ Clin. Oncol. (1995) 13:2230–2237.
   Google Scholar
• GRAHAM MV, JAHANZEB M, DRESLER C eta].: Preliminary results of a Phase I study of topotecan plus thoracic radiotherapy for locally advanced non-small cell lung cancer (NSCLC). Proc. ASCO (1994) 13:1132.
   Google Scholar
• KUDELKA AP, TRESUKOSOL D, EDWARDS CL etaL: Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. J. Clin. Oncol. (1996) 14:1552–1557.
   PubMed Web of Science ®Google Scholar
• CREEMERS GJ, BOLIS M, GORE M et al.: Topote can, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. J. Clin. Oncol (1996) 14:3056-3061. Activity of topotecan in recurrent ovarian cancer.
   Google Scholar
• GORE M, BOLTS B, CREEMERS G et al.: A Phase II study of topotecan as second-line therapy given as five daily doses for advanced epithelial ovarian cancer. Ann. Oncol. (1996) 7 (Sup pl.) :474.
   Google Scholar
• GWYTHER SJ, BOLTS G, TEN BOKKEL HUININK W eta].: Experience with independent radiological review dur-ing a topotecan trial in ovarian cancer. Ann. Oncol (1996) 7\(Suppl. 5):3250.
   Google Scholar
• BOLTS G, MALSTROM H, MANGIONI C eta].: Efficacy of topotecan in advanced epithelial ovarian cancer after failure of platinum and paclitaxel: International Topo-tecan Study Group Trial. Ann. Oncol (1996) 7\(Suppl. 5):3210.
   Google Scholar
• ARMSTRONG D, ROWINSKY E, DON EHOWER R et a].: A Phase 11 trial of topotecan as salvage therapy in epi-thelial ovarian cancer. Proc. AACR (1995) 14:275.
   Google Scholar
• CARMICHAEL J, GORDON A, MALFETANO J etal.: Topote-can, a new active drug, vs. paclitaxel in advanced epithelial ovarian carcinoma: International Topotecan Study Group. Proc. ASCO (1996) 15:765A. Activity of topotecan vs. paclitaxel in advanced ovarian cancer.
   Google Scholar
• CARMICHAEL J: Hycamtin: expanding options in ovar-ian cancer. ESMO Satellite Symposium. Vienna (1996).
   Google Scholar
• HOCHSTER H, SPEYER J, WADER S et a].: Activity of topotecan (TPT) 21-day infusion in platinum-treated ovarian cancer and pharmacodynamics of topo-1 de-pletion (a NYGOG study). Ann. Oncol (1996) 7\(Suppl. 5):326P.
   Google Scholar
• SCHILLER JH, KIM K, HUTSON P eta].: Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung an Eastern Cooperative Oncol-ogy Group Trial. J. Gun. Oncol. (1996) 14:2345–2352.
   Google Scholar
• ARDIZZONI A, HANSEN H, DOMBERNOWSKY P et al:
   Google Scholar
• ••Phase 11 study of topote can in refractory and sensitivesmall cell lung cancer. Proc. ECCO 8 (1995) 31A\(Suppl. 5):84A. Activity of topotecan in SCLC.
   Google Scholar
• PEREZ-SOLER R, GLISSON B, LEE J eta].: Phase II study of topotecan in patients with small cell lung cancer (SCLC) refractory to etoposide. Proc. ASCO (1995) 14:355.
   Google Scholar
• MANAGOLD C, PAVVEL JV, SCHEITHAUER W et al.: Response of SCLC brain metastases on topotecan (SK&F 104864) therapy. Proc. ESMO (1996):5090. Response to topotecan in brain metastases.
   Google Scholar
• PEREZ-SOLER R, FOSELLA FV, GLISSON BS etal: Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with previous chemotherapy. J. Clin. Oncol (1996) 14:503–513.
   PubMed Web of Science ®Google Scholar
• LYNCH TJ, KALISH L, STRAUSS G eta].: Phase II study of topotecan in metastatic non-small-cell lung cancer. J. Clin. Oncol. (1994) 12:347–352.
   Google Scholar
• WEITZ, JJ, SIN-HO JUNG, MARSCHKE RF et al: Random-ized Phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung card-noma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial. Proc. ASCO (1995) 14:348.
   Google Scholar
• CREEMERS GJ, WANDERS J, GAMUCCI T et al.: Topotecan in colorectal cancer: a Phase II study of the EORTC early clinical trial group. Ann. Oncol (1995) 6:844–846.
   PubMed Web of Science ®Google Scholar
• CREEMERS GJ, GERRITS CHJ, PLANTING ASTh eta].: Phase 11 study with topotecan administered as a 21-days con-tinuous infusion to patients with colorectal cancer. Proc. ECCO 8 (1995) 31A\(Suppl. 5):700A.
   Google Scholar
• BERAN M, KANTARJIAN H, O'BRIEN S et al: Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomono-cytic leukemia. Blood (1996) 88:2473–2479.
   PubMed Web of Science ®Google Scholar
• MACDONALD D, CAIRNCROSS G, STEWART D eta].: Phase II study of topotecan in patients with recurrent malig-nant glioma. Ann. Oncol. (1996) 7:205–207.
   Google Scholar
• BROCK CS, BOWER M, EVANS H, HUDSON I, NEWLANDS ES: Phase II trial of topotecan as a continuous intrave-nous infus ion in patients with high gra de gliomas. Ann. Oncol. (1996) 7\(Suppl. 5):635P.
   Google Scholar
• CHANG AY, GARROW G, BOROS L et al.: Clinical and laboratory studies of topotecan in breast cancer. Proc. ASCO (1995) 14:105.
   Google Scholar
• NODA K, SASAKI H, YAMAMOTO K eta].: Phase 11 trial of topotecan for cervical cancer of the uterus. Proc. ASCO (1996) 15:754A.
   Google Scholar
• PUC HS, BAJORIN DF, BOSL GJ, AMSTERDAM A, MOTZER RJ: Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors. Invest. New Drugs (1995) 13:163–165.
   PubMed Web of Science ®Google Scholar
• ROBERT D, WHEELER RH, MOLTHROP DC et al.: Phase IIstudy of topotecan in advanced head and neck cancer: identification of an active new agent. Proc. ASCO (1994) 13:281.
   Google Scholar
• SMITH RE, LEWD, RODRIQUEZ G, TAYLOR SA, SCHULLER D: Evaluation of topotecan in recurrent or metastatic head and neck cancer. Proc. ASCO (1996) 15:868A.
   Google Scholar
• O'BRIEN S, KANTARJIAN H, ELLIS A et al.: Topotecan in chronic lymphocytic leukemia. Cancer (1995) 75:1104–1108.
   Google Scholar
• KRAUT EH, STAUBUS A, MAYERNICK D, KING G, BALCER-ZAK SP: Phase II trial of topotecan in metastatic malig-nant melanoma. Proc. AACR (1995) 36:238.
   Google Scholar
• JANIK J, MILLER L, SMITH J et al.: Prechemotherapy granulocyte macrophage colony stimulating factor pre-vents topotecan induced neutropenia. Proc. ASCO (1993) 12:A1507.
   Google Scholar
• SUGARMAN SM, PAZDUR R, DAUGHERTY K eta].: A Phase II trial of topotecan (TPT) for the treatment of unres ect-able pancreatic cancer. Proc. ASCO (1994) 13:224.
   Google Scholar
• SCHER R, LUSCH CJ, GREEN F et al.: Phase II trial of topote can in advanced pancreatic cancer. Proc. ECCO 7 (1993) 29A\(Suppl. 6):542.
   Google Scholar
• MAKSYMIUK AW, JUNG SH, MARSCHKE RF eta].: Phase 11 trial of topotecan in pleural mesothelioma: a North Central Cancer Treatment Group (NCCTG) trial. Proc. ASCO (1995) 14:435.
   Google Scholar
• HUDES GR, KOSIEROWSKI R, GREENBERG R et al.: Phase II study of topotecan in metastatic hormone-refractory prostate cancer. Invest. New Drugs (1995) 13:235–240.
   PubMed Web of Science ®Google Scholar
• LAW TM, ILSON DH, MOTZER RJ: Phase II trial of topote-can in patients with advanced renal cell carcinoma. Invest New Drugs (1994) 12:143–145.
   PubMed Web of Science ®Google Scholar
• BRAMVVELL VHC, EISENHAUER EA, BLACKSTEIN M et al.: Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann. Oncol. (1995) 6:847–849.
   PubMed Web of Science ®Google Scholar
• NEIJT JP, TEN BOKKEL HUININK WW, VANDER BURG MEL et al.: Long-term survival in ovarian cancer: mature data from the Netherlands Joint Study Group for Ovarian Cancer. Eur. J. Cancer (1991) 27:1367–1372.
   Google Scholar
• EISENHAUER EA, TEN BOKKEL HUININK WW, SVVENER-TON KD et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J. Clin. Oncol. (1994) 12:2654–2666.
   PubMed Web of Science ®Google Scholar
• TRIMBLE EL, ADAMS JD, VENA D et al.: Paclitaxel for platinum refractory ovarian cancer: results from the first 1000 patients registered to National Cancer Insti-tute Treatment Referral Centre 9103../. Clin. Oncol. (1993) 11:2405–2410.
   Google Scholar
• MORSTYN G, IHDE DC, LICHTER AS et al.: Small cell lung cancer 1973-1983: early progress and recent obstacles. Int. J. Rad. Oncol Biol. Phys. (1984) 10:515–539.
   PubMed Web of Science ®Google Scholar
• LIVINGSTON RB, TRAUTH CJ, GREENSTREET RL: Small cell carcinoma: clinical manifestations and behavior with treatment. In: Small Cell Lung Cancer. Greco FA, Oldham RK, Bunn PA, Jr. (Eds.), Gruen & Straton, New York (1980:285–300.
   Google Scholar
• MASUDA N, FUKUOKA M, KUSUNOKI Y et al.: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J. Clin. Oncol. (1992) 10:1225–1229.
   PubMed Web of Science ®Google Scholar
• PUJOL JL, LE CHEVALIER T, DOUILLARD JY et al: CPT-11 (irinotecan) in pretreated small cell lung cancer (S CLC): a Phase II study in patients progressing after a first response (preliminary results). Eur. J. Cancer (1995) 31 (Suppl. 5):S21.
   Google Scholar
• LATREILLE J, CORMIER Y, MARTINS H et al: Phase II study of docetaxel (Taxotere) in patients with previously untreated extensive small cell lung cancer. A trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). Invest New Drugs (1995) 13:343–345.
   Google Scholar
• SMYTH JF, SMITH IE, SESSA P et al.: Activity of docetaxel (Taxotere) in small cell lung cancer. Eur. J. Cancer (1994) 30A:1058–1060.
   PubMed Web of Science ®Google Scholar